Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Materials (Basel) ; 15(19)2022 Sep 27.
Artículo en Inglés | MEDLINE | ID: mdl-36234053

RESUMEN

Cageless ball bearings with discrete grooves in the outer raceway enable the dispersion of rolling elements. Once worn, the discrete groove can cause the rolling element to discretely fail. This paper presents the discrete element method to investigate the wear of discrete grooves in cageless bearings from the standpoint of bond fracture. In conjunction with the structural characteristics of bearing races with discrete slots, we propose a hexagonal close-spaced spherical particle arrangement, in which the discrete slots are discretized into particles of the same size that are connected by bonds. The contact model and contact force equation between the rolling elements and the aggregate elements are established, and the external force on the aggregate elements is calculated. Under the influence of an external force and the arrangement of particles in the aggregate element, the internal force transfer equation of different layers and different particles is derived, and the internal force of the particles in the aggregate unit is calculated. In accordance with Hertz-Mindline theory, the bonding model of discrete groove particles is established, the size of the particle shedding cohesive force during bond fracture is determined, and the wear degree of discrete grooves is characterized by comparing the cohesive force and internal force. Numerical solutions and wear tests are combined. Bond fracture can accurately characterize the wear of discrete grooves. This approach offers theoretical guidance for cageless bearing design.

2.
Front Immunol ; 12: 731527, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34804015

RESUMEN

Advanced hepatocellular carcinoma (HCC) remains a formidable health challenge worldwide, with a 5-year survival rate of 2.4% in patients with distant metastases. The hepatocyte growth factor/cellular-mesenchymal-epithelial transition (HGF/c-Met) signaling pathway represents an encouraging therapeutic target for progressive HCC. Tivantinib, a non-adenosine triphosphate-competitive c-Met inhibitor, showed an attractive therapeutic effect on advanced HCC patients with high MET-expression in phase 2 study but failed to meet its primary endpoint of prolonging the overall survival (OS) in two phase 3 HCC clinical trials. Seven clinical trials have been registered in the "ClinicalTrials.gov" for investigating the safety and efficacy of tivantinib in treating advanced or unresectable HCC. Eight relevant studies have been published with results. The sample size ranged from 20 to 340 patients. The methods of tivantinib administration and dosage were orally 120/240/360 mg twice daily. MET overexpression was recorded at 34.6% to 100%. Two large sample phase 3 studies (the METIV-HCC study of Australia and European population and the JET-HCC study of the Japanese population) revealed that tivantinib failed to show survival benefits in advanced HCC. Common adverse events with tivantinib treatment include neutropenia, ascites, rash, and anemia, etc. Several factors may contribute to the inconsistency between the phase 2 and phase 3 studies of tivantinib, including the sample size, drug dosing, study design, and the rate of MET-High. In the future, high selective MET inhibitors combined with a biomarker-driven patient selection may provide a potentially viable therapeutic strategy for patients with advanced HCC.


Asunto(s)
Antineoplásicos/uso terapéutico , Carcinoma Hepatocelular/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/uso terapéutico , Proteínas Proto-Oncogénicas c-met/antagonistas & inhibidores , Pirrolidinonas/uso terapéutico , Quinolinas/uso terapéutico , Adolescente , Adulto , Anciano , Antineoplásicos/efectos adversos , Carcinoma Hepatocelular/enzimología , Carcinoma Hepatocelular/mortalidad , Carcinoma Hepatocelular/patología , Ensayos Clínicos como Asunto , Femenino , Humanos , Neoplasias Hepáticas/enzimología , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/patología , Masculino , Persona de Mediana Edad , Terapia Molecular Dirigida , Inhibidores de Proteínas Quinasas/efectos adversos , Proteínas Proto-Oncogénicas c-met/metabolismo , Pirrolidinonas/efectos adversos , Quinolinas/efectos adversos , Transducción de Señal , Resultado del Tratamiento , Adulto Joven
3.
PLoS One ; 9(5): e98159, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24878582

RESUMEN

The effects of the molecular weight (MW) and charge density (CD) of cationic polyacrylamide (CPAM) on sludge dewatering and moisture evaporation were investigated in this study. Results indicated that in sludge conditioning, the optimum dosages were 10, 6, 6, 4, and 4 mg g(-1) CPAM with 5 million MW and 20% CD, 5 million MW and 40% CD, 3 million MW and 40% CD, 8 million MW and 40% CD, and 5 million MW and 60% CD, respectively. The optimum dosage of CPAM was negatively correlated with its CD or MW if the CD or MW of CPAM was above 20% or 5 million. In the centrifugal dewatering of sludge, the moisture content in the conditioned sludge gradually decreased with the extension of centrifugation time, and the economical centrifugal force was 400×g. The moisture evaporation rates of the conditioned sludge were closely related to sludge dewaterability, which was in turn significantly correlated either positively with the solid content of sludge particles that were >2 mm in size or negatively with that of particles measuring 1 mm to 2 mm in diameter. During treatment, sludge moisture content was reduced from 80% to 20% by evaporation, and the moisture evaporation rates were 1.35, 1.49, 1.62, and 2.24 times faster in the sludge conditioned using 4 mg g(-1) CPAM with 5 million MW and 60% CD than in the sludge conditioned using 4 mg g(-1) CPAM with 8 million MW and 40% CD, 6 mg g(-1) CPAM with 5 million MW and 40% CD, 6 mg g(-1) CPAM with 3 million MW and 40% CD, and 10 mg g(-1) CPAM with 5 million MW and 20% CD, respectively. Hence, the CPAM with 5 million MW and 60% CD was ideal for sludge dewatering.


Asunto(s)
Resinas Acrílicas/química , Desecación/métodos , Aguas del Alcantarillado/química , Agua/química , Centrifugación , Filtración , Peso Molecular , Tamaño de la Partícula , Volatilización
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA